SCHEMBL9947101

SCHEMBL9947101

CCCCOC(=O)CNCl

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
NAAA Q02083 1/20 0.50
ATM Q13315 1/20 0.47
FAAH O00519 2/20 0.46
DGKA P23743 1/20 0.45
HPGD P15428 2/20 0.44
TSHR P16473 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
PPARG P37231 1/20 0.43
NCOA2 Q15596 1/20 0.43
NCOA1 Q15788 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
RAD52 P43351 1/20 0.43
EPHX1 P07099 1/20 0.42
ACHE P22303 6/20 0.41
HCAR2 Q8TDS4 1/20 0.41
HTR2C P28335 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9912809 0.83 HTR2C (0.54) ALDH1A1NAAAATMFAAHDGKA
SCHEMBL8390838 0.83 ALDH1A1 (0.54) ALDH1A1NAAAATMFAAHDGKA
SCHEMBL7253674 0.81 ALDH1A1 (0.52) ALDH1A1NAAAATMFAAHDGKA
SCHEMBL807476 0.81 ALDH1A1 (0.52) ALDH1A1NAAAATMFAAHDGKA
SCHEMBL152233 0.80 ALDH1A1 (0.61) ALDH1A1NAAAATMFAAHDGKA
SCHEMBL10154353 0.79 ALDH1A1 (0.50) ALDH1A1NAAAATMFAAHDGKA
SCHEMBL1515500 0.79 ALDH1A1 (0.50) ALDH1A1NAAAATMFAAHDGKA
SCHEMBL21578651 0.79 ALDH1A1 (0.50) ALDH1A1NAAAATMFAAHDGKA
Hydrochloric Acid SCHEMBL7367029 0.79 ALDH1A1 (0.50) ALDH1A1NAAAATMFAAHDGKA
SCHEMBL17970767 0.79 ALDH1A1 (0.50) ALDH1A1NAAAATMFAAHDGKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149632-A1 GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY THE MEDICINES COMPANY (US) 2012-06-14 US disclosed
WO-2011019839-A2 GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY THE MEDICINES COMPANY (US) 2011-02-17 WO disclosed
US-20100216834-A1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-08-26 US disclosed
US-20080280945-A1 Crystalline forms of an HIV integrase inhibitor MERCK SHARP & DOHME CORP. 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216834-A1 HIV INTEGRASE INHIBITORS REV1, CDK9, INTS9 ALDH1A1 2670/4885NAAA 2308/4885ATM 2689/4885
US-20080280945-A1 Crystalline forms of an HIV integrase inhibitor TYMP, SAMHD1, ACIN1 ALDH1A1 3635/4885NAAA 2928/4885ATM 1672/4885
US-20120149632-A1 GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY NGLY1, LGALS3BP, GYPA ALDH1A1 4197/4885NAAA 906/4885ATM 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.